Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5309743 | 0.85 | ALDH1A1 (0.48) | HTTCA2NAMPT | |
| SCHEMBL5306727 | 0.85 | LMNA (0.41) | — | |
| SCHEMBL5312057 | 0.84 | SCD (0.52) | MGLLGABRA5 | |
| SCHEMBL5306123 | 0.83 | EGLN1 (0.41) | HTTEGLN1 | |
| SCHEMBL5312497 | 0.82 | SMN1; SMN2 (0.44) | HTTEGLN1MGLLCA12CA1 | |
| SCHEMBL5307375 | 0.80 | SCD (0.36) | HTTMGLLCA12CA1CA2 | |
| SCHEMBL5312492 | 0.78 | EGLN1 (0.42) | HTTEGLN1 | |
| SCHEMBL5309581 | 0.77 | SCD (0.44) | HTTEGLN1 | |
| SCHEMBL5306119 | 0.77 | EGLN1 (0.42) | HTTEGLN1MGLL | |
| SCHEMBL5309646 | 0.77 | SCD (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007046867-A2 | PIPERIDINE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-04-26 | — | — | WO | disclosed |